Table 5.
Glioma | + | Supernate ± Medium (v:v) | % Mitotic | % Apoptotic |
---|---|---|---|---|
04-11-MG | + | None / new medium | 4 | 5.0 |
04-11-MG | + | Coincubation supernate / new medium (1:1) | 0 | 3.0 |
04-11-MG | + | Coincubation supernate / new medium (2:1) | 3 | 3.0 |
04-11-MG | + | Coincubation supernate / none | 1 | 3.0 |
04-11-MG | + | TALL-104 cell controlb | 1 | 23.0 |
10-08-MG | + | None / new medium | 10 | 1.6 |
10-08-MG | + | Coincubation supernate / new medium (1:1) | 1 | 4.8 |
10-08-MG | + | Coincubation supernate / new medium (2:1) | 2 | 4.2 |
10-08-MG | + | Coincubation supernate / none | 0 | 4.0 |
10-08-MG | + | TALL-104 cell controlb | 0 | 64.8 |
14-07-MG | + | None / new medium | 6 | 2.0 |
14-07-MG | + | Coincubation supernate / new medium (1:1) | 1 | 2.0 |
14-07-MG | + | Coincubation supernate / new medium (2:1) | 3 | 3.0 |
14-07-MG | + | Coincubation supernate / none | 2 | 5.0 |
14-07-MG | + | TALL-104 cell controlb | 0 | 40.0 |
Four-hour morphologic assessment of H&E-stained glioma cells attached to 4-well chamber slides. After coincubation of human glioma cells with TALL-104 cells, supernate was collected and clarified. Clarified supernate, either neat or diluted (v/v) with fresh medium, was then added to brain tumor cell monolayers. After a 4-h incubation period, 400 cells were examined and scored as normal, mitotic, or apoptotic.
The 3 glioma cells explants were coincubated with TALL-104 cells as a positive control.